Patent classifications
C07K16/242
Compositions and methods for combating drug-resistant cancers
Compositions and methods for reducing or overcoming acquired resistance to cetuximab are provided. Compositions and methods for treatment of cetuximab-resistant cancers are also provided. In addition, methods of inhibiting the growth of EGFR-expressing tumor cells that are resistant to cetuximab therapy are provided herein.
PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
Process for manipulating the level of glycan content of a glycoprotein
The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
COMPOSITIONS AND METHODS FOR COMBATING DRUG-RESISTANT CANCERS
Compositions and methods for reducing or overcoming acquired resistance to cetuximab are provided. Compositions and methods for treatment of cetuximab-resistant cancers are also provided. In addition, methods of inhibiting the growth of EGFR-expressing tumor cells that are resistant to cetuximab therapy are provided herein.
MODIFIED ANTIBODIES CONTAINING MODIFIED IGG2 DOMAINS WHICH ELICIT AGONIST OR ANTAGONISTIC PROPERTIES AND USE THEREOF
Through a combination of in vitro and in vivo approaches, the inventors show that human IgG2 (h2) delivers unique FcR-independent agonistic activity to anti-CD40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1BB and CD28. Investigation of an anti-human CD40 mAb, LOB7.4, revealed that the unique activity of h2 was dependent upon the precise arrangement of hinge and CH1 disulfide bonds. Chemical shuffling or mutagenesis to lock LOB7.4 into either a more flexible h2A or more compact h2B conformation endowed antagonistic and agonistic properties, respectively. Engineering of h2 in this way allows development of reagents with either immunostimulatory or immunosuppressive characteristics, with direct implication for the design of therapeutic mAb agents and fusion proteins.
VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.